BioMarin drops 17% after Ascendis data seen as threat to Voxzogo
hapabapa/iStock Editorial via Getty Images BioMarin Pharmaceuticals (NASDAQ:BMRN) is Down ~17% On Monday, it became known that an achondroplasia candidate ...
hapabapa/iStock Editorial via Getty Images BioMarin Pharmaceuticals (NASDAQ:BMRN) is Down ~17% On Monday, it became known that an achondroplasia candidate ...